A Phase 2 interventional study of Neoadjuvant Pembrolizumab and low dose neoadjuvant boost in Breast Cancer, Triple Negative Breast Cancer (TNBC) and HER2-Negative Breast Carcinoma, sponsored by UNC Lineberger Comprehensive Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by UNC Lineberger Comprehensive Cancer Center · Phase 2, Interventional, and Treatment
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 645 studies in Triple Negative Breast Neoplasms with a site in United States — 159 open to participants now, 263 under way, 16 of them phase 3. Triple Negative Breast Neoplasms · United States.
Among the 645 studies in Triple Negative Breast Neoplasms with a site in United States, this one is the 401st largest by planned enrollment of the 605 interventional ones that give a count, is one of 38 that started in 2026, is one of 191 in phase 2, reaches primary completion later than 157 of the 262 other live ones, and was the 614th registered.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.
Browse Triple Negative Breast Neoplasms studies →159 of the 645 studies in Triple Negative Breast Neoplasms with a site in United States are open now. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 18–75 · Women only
Medical University of South Carolina · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
Stephen Shiao · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
645 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 353 · Phase 2 300 · Phase 3 29
First in 2001; this study’s year is marked. 38 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 32 is below the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.
Median enrollment 52 across the 605 interventional studies, 90 across the 38 observational. Of the 339 that completed or were terminated, 179 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
319 of 645 have an industry lead sponsor. The 10 most frequent:
UNC Lineberger Comprehensive Cancer Center is the lead sponsor of 431 studies on the registry; 96 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
UNC Lineberger Comprehensive Cancer Center has 8 studies filed under Triple Negative Breast Neoplasms — fewer than ten, so there is no comparison to draw.
93 of the studies in Triple Negative Breast Neoplasms with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05382286Phase 3Gilead SciencesStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | 2027-02 |
| NCT05633654Phase 3Gilead SciencesStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | 2027-06 |
| NCT04768426Stanford UniversitySerial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer | 2026-11 |
| NCT06545331ExelixisStudy of XB010 in Subjects With Solid Tumors | 2026-11-23 |
| NCT02276443M.D. Anderson Cancer CenterMolecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative | 2026-11-30 |
Add all 93 to your calendar (.ics) → With an account.
Among the 645 studies in Triple Negative Breast Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective radiation dose-finding, phase 2 expansion study of the Triple Negative (TN) cohort of the multicenter randomized study P-RAD (A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast Cancer; NCT04443348) that seeks to establish the optimal dose of radiation therapy (RT) to elicit an immune response when combined with immune checkpoint inhibitor (ICI) in breast cancer patients. Eligible subjects include women or men with operable, lymph node-positive, triple negative (TN) breast cancer who are candidates for standard of care neoadjuvant chemo-immunotherapy (NAC) based on the KEYNOTE-522 clinical trial. Thirty-two (n=32) patients will be randomized 1:1 to receive either low RT boost (9Gy total) or high RT boost (24Gy total). All RT will be delivered to the intact breast tumor in 3 daily fractions over 3 days.
In the Neoadjuvant Phase, the first cycle (C1) of pembrolizumab (200 mg i.v.) will be administered within 0-2 days of initiating RT. Participation in this study requires availability of residual diagnostic tissue biopsies of the primary tumor and metastatic lymph node for research use. If this tissue is not available, baseline research biopsies will be performed. Additionally, a research biopsy of the breast tumor and lymph node is required on Day 10-14 of C1 of pembrolizumab. After completion of the research biopsy in Week 2, the participants can commence standard-of-care neoadjuvant chemotherapy and pembrolizumab at the discretion of their medical oncology provider. After completing NAC, participants will undergo standard of care surgical resection of the breast and axillary lymph nodes, at the discretion of their surgical oncology provider. In the Adjuvant Phase, participants will receive standard of care adjuvant systemic therapy and standard of care adjuvant radiotherapy (if indicated), although recognizing that the breast tumor boost portion of this treatment has already been administered preoperatively. Except for late radiation adverse reactions of special interest, which will be followed yearly for up to 5 years, follow-up will occur every 6 months for 3 years.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.
This study's planned enrollment of 32 is below the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.
Browse Triple Negative Breast Neoplasms studies →UNC Lineberger Comprehensive Cancer Center is the lead sponsor of 431 studies on the registry; 96 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In order to participate in this study, a subject must meet all of the eligibility criteria outlined below.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a low dose radiation therapy boost in 3 fractions (3Gy x 3 fraction = 9Gy total).
Drug: Neoadjuvant Pembrolizumab · Radiation: low dose neoadjuvant boost
Participants will receive a high dose radiation therapy boost in 3 fractions (8Gy x 3 fraction = 24Gy total).
Drug: Neoadjuvant Pembrolizumab · Radiation: High dose neoadjuvant boost
200 milligrams per square meter Neoadjuvant Pembrolizumab will be administered intravenously.
An external beam radiotherapy boost of 9Gy total will be administered over 3 fractions.
An external beam radiotherapy boost of 24Gy total will be administered over 3 fractions.
Nodal Pathologic Complete Response rate(pCR)
Nodal pCR is defined in a patient with no residual cancer cells in all sampled regional lymph nodes following completion of neoadjuvant systemic therapy as assessed by the study pathologist at the time of definitive surgery. Nodal pCR rates will be calculated and analyzed separately for patients receiving low versus high dose RT. A pooled analysis, incorporating the corresponding (3Gyx3 or 8Gyx3) patient cohort from the P-RAD trial, will be performed.
Time frame: Time of surgery (24 week)
The CD3+/CD8+ T cell Breast post-treatment biopsy
The CD3+/CD8+ T cell Breast Immunoscore of post-treatment biopsy samples represents an average of percentage ranked scores for (i) CD3+ density in intra-tumoral region, (ii) CD3+ density in peri-tumoral region, (iii) CD8+ density in intra-tumoral region, and (iv) CD8+ density in peri-tumoral region. The reference cohort for determining percentage ranks will be the pre-treatment biopsy samples.
Time frame: Time of surgery (24 week)
Composite pathologic complete response (pCR) (ypT0/Tis ypN0)
Composite pCR =T0/Tis and pN0 will be defined as the percentage of patients with Tis/T0 disease in the breast and no evidence of residual cancer cells in all sampled regional lymph nodes following completion of neoadjuvant systemic therapy, assessed by the study pathologist at the time of definitive surgery.
Time frame: Time of surgery (24 week)
Total residual cancer burden (RCB)
RCB will be evaluated by the study pathologist and defined based on residual tumor size and/or area, overall cellularity, and extent of lymph node involvement.
Time frame: Time of surgery (24 week)
Nodal pathologic complete response (pCR)
Nodal pCR is defined as absence of residual cancer cells in all sampled regional lymph nodes.
Time frame: Time of surgery (24 week)
Composite pathologic complete response (pCR)
Composite pCR rate is measured by ypTis/T0 disease in the breast and the absence of residual cancer cells in all sampled regional lymph nodes.
Time frame: Time of surgery (24 week)
Changes in pre- versus post-treatment intra-tumoral, peri-tumoral, and stromal CD3+ or CD8+ T cell percentages
Intra-tumoral, peri-tumoral, and stromal CD3+ and CD8+ T-cell densities will be measured in biopsy and surgical specimens and compared. Pan-cytokeratin staining will be used to identify tumor regions, and the percentages will be analyzed.
Time frame: Time of surgery (24 week)
Change in tumor-infiltrating lymphocyte (TIL)
Tumor-infiltrating lymphocyte (TIL) counts will be assessed on hematoxylin and eosin (H\&E)-stained biopsy and surgical specimens using the Salgado criteria, which evaluate the percentage of stromal area occupied by lymphocytes following standardized guidelines. The values in biopsy and surgical specimens and compared.
Time frame: Time of surgery (24 week)
Change in Programmed cell death 1 ligand 1(PD-L1)
Changes in PD-L1 expression levels will be assessed using the U.S. FDA-approved 22C3 pharmDx companion diagnostic assay to determine the Combined Positive Score (CPS). A CPS greater than 1 will be considered PD-L1 positive. The values in biopsy and surgical specimens and compared.
Time frame: Time of surgery (24 week)
Changes in intratumoral, peri-tumoral, and stromal CD4+Foxp3+ T regulatory cell densities
Changes in intratumoral, peri-tumoral, and stromal CD4+FOXP3+ regulatory T-cell densities will be quantified using quantitative immunofluorescence (QIF) for CD4 and FOXP3 in formalin-fixed, paraffin-embedded (FFPE) tumor biopsy and surgical specimens. Pan-cytokeratin staining will be used to identify tumor regions.
Time frame: Time of surgery (24 week)
Adverse Events
Adverse events will be classified and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE v5.0), at 30 days after investigational pembrolizumab administration. The number of observed AEs will be reported.
Time frame: Up to 60 weeks
Invasive disease-free survival (iDFS)
iDFS will be defined as the time from completion of surgery to the first occurrence of the following events: invasive ipsilateral, local, regional, or distant recurrence, or death due to breast cancer.
Time frame: Up to 5 years
Event-free survival (EFS)
EFS will be defined as the time from the initiation of the study treatment to any of the following events: progression of disease (precluding surgery), recurrence (local or distant), or death due to any cause.
Time frame: Up to 5 years
Quality of life Global Health PROMIS in Low Dose Radiotherapy Boost Group
Quality of life will be assessed by Patient-Reported Outcomes Measurement Information System (PROMIS) tool developed by the National Institutes of Health (NIH) before and after treatment. It is designed to measure a patient's overall physical, mental, and social health using a brief and standardized questionnaire. Responses are collected using a 5-point Likert scale (1 = Poor, 5 = Excellent), summed into raw scores, and converted to standardized T-scores (mean = 50, SD = 10; range \~20-80), with higher scores indicating better health.
Time frame: Baseline, Week 2, Week 8, Week 14, and Week 20, 6 months post-surgery, and monthly for up to 3 years
Quality of life BREAST-Q in Low Dose Radiotherapy Boost Group
Patient-reported outcomes related to breast surgery will be assessed using the BREAST-Q questionnaire, a validated instrument measuring satisfaction with breasts, psychosocial well-being, physical well-being, and sexual well-being. Most items are answered on a 4- to 5-point Likert scale, for example: Satisfaction: "Very dissatisfied" → "Very satisfied" or Frequency/impact: "Never" → "Always" or "Not at all" → "Very much. "Responses are scored according to the BREAST-Q scoring system and transformed to a 0-100 scale, with higher scores indicating greater satisfaction or better quality of life.
Time frame: Baseline, Week 2, Week 8, Week 14, and Week 20, 6 months post-surgery, and monthly for up to 3 years
The Was It Worth It (WIWI) in Low Dose Radiotherapy Boost Group
The Was It Worth It (WIWI) instrument, also called the Trial Satisfaction survey, is a validated patient-reported outcome measure designed to assess participants' experiences and satisfaction with clinical trial participation. It evaluates whether patients feel that joining the trial was worthwhile and captures their overall perception of the trial experience. Responses are collected using a Likert-type scale (3 to 5 points) or categorical options, with higher scores indicating a more positive perception of trial participation. Scores will be summarized to assess overall patient satisfaction and the perceived value of trial involvement.
Time frame: Baseline, Week 2, Week 8, Week 14, and Week 20, 6 months post-surgery, and monthly for up to 3 years
Quality of life Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Low Dose Radiotherapy Boost Group
PRO-CTCAE, which collects information on the frequency, severity, interference, and presence or absence of symptoms such as pain, fatigue, nausea, and cutaneous side effects including rash and hand-foot syndrome. These toxicities are selected because they can be meaningfully reported from the patient perspective. PRO-CTCAE responses are scored from 0 to 4, or 0/1 for absent/present items. If the first response in an item set is the lowest on the scale (e.g., 'Never' for frequency or 'None' for severity), any conditionally branched items are scored as 0 and not treated as missing.
Time frame: Baseline, Week 2, Week 8, Week 14, and Week 20, 6 months post-surgery, and monthly for up to 3 years
Comparison tumor-infiltrating lymphocyte (TIL)
Differences in tumor-infiltrating lymphocyte (TIL) between low and high dose levels will be assessed by hematoxylin and eosin (H\&E)-stained biopsy and surgical specimens using the Salgado criteria, which evaluate the percentage of stromal area occupied by lymphocytes following standardized guidelines. The values in biopsy and surgical specimens and compared. Differences in TIL between low and high dose levels (3Gyx3 or 8Gyx3) will be assessed by H\&E.
Time frame: Time of surgery (24 week)
Plan to share: No
Started Mar 2026 (actual). Primary completion is estimated for Nov 2027, 20 months after the start.
Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 20 months is below that.
Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Triple Negative Breast Neoplasms →
UNC Lineberger Comprehensive Cancer Center →